How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

542 results for

Famciclovir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Blocking virus replication during acute MCMV infection paradoxically prolongs antigen presentation and increases the CD8+ T cell response by preventing type I IFN-dependent depletion of DCs Full Text available with Trip Pro

Blocking virus replication during acute MCMV infection paradoxically prolongs antigen presentation and increases the CD8+ T cell response by preventing type I IFN-dependent depletion of DCs Increasing amounts of pathogen replication usually lead to a proportionate increase in size and effector differentiation of the CD8+ T cell response, which is attributed to increased Ag and inflammation. Using a murine CMV that is highly sensitive to the antiviral drug famciclovir to modulate virus

2016 Journal of immunology (Baltimore, Md. : 1950)

82. Intérêt de la thérapie antivirale par voie orale dans le traitement des nécroses rétiniennes aigues Full Text available with Trip Pro

acuity. After the discovery of this disease using polymerase chain reaction (PCR) and immune load coefficient (ILC) usually by puncturing the cornea to evacuate the aqueous humour, the confirmation of this diagnosis allows for faster optimization of disease management decreasing the time required to confirm the diagnosis. ARN syndrome is associated with a very poor prognosis. Recent studies have shown that oral antiviral (valaciclovir, famciclovir and valganciclovir) and intravitreal therapies (...) as early as possible in order to limit bilateralization and the occurrence of complications. This study confirms that oral antiviral (valacyclovir, famciclovir and valganciclovir) and intravitreal therapies without initial intravenous treatment are an effective treatment for RNA.

2016 The Pan African medical journal

83. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases Full Text available with Trip Pro

better than those reported in the studies that tested acyclovir, valacyclovir, and famciclovir. The current paper reports the effect of suppressive treatment with Gene-Eden-VIR/Novirin on the duration of outbreaks, in severe and mild genital herpes cases.The framework was a retrospective chart review. The population included 137 participants. The treatment was 1-4 capsules per day. The duration of treatment was 2-48 months. The study included three controls: baseline, no-treatment, and dose

2016 Clinical and translational medicine

84. A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional

of immunoglobulins and/or any blood products within 3 months prior to Visit Month 0 of study ZOSTER-049 or planned administration during the study period. Prolonged use (> 14 consecutive days) of oral and/or parenteral antiviral agents that are active against VZV (acyclovir, valacyclovir, famciclovir, etc. ) and planned to be used during the study period for an indication other than to treat suspected or confirmed HZ or an HZ-related complication (topical use of these antiviral agents is allowed). Important

2016 Clinical Trials

85. Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity

mg/kg (TBW for normal weight patients and ABW40 for obese patients) as part of their routine care Weight > 190% of ideal body weight (IBW) for "obese" patients or weight 80-120% of IBW for matched control patients. Exclusion Criteria: Receipt of acyclovir or a pro-drug of acyclovir (valacyclovir, ganciclovir, valganciclovir, famciclovir) in the prior 24 hours Serum creatinine >1.5 mg/dL Hypersensitivity to acyclovir Patients requiring ventilator support or vasopressors in the prior 24 hours

2016 Clinical Trials

86. HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

involvement which would require ventricular, cerebellar or brainstem inoculation or would require access through a ventricle in order to deliver treatment Prior participant in experimental viral therapy (e.g., adenovirus, retrovirus or herpes virus protocol) Required steroid increase within 1 week prior to injection Known HIV seropositivity Concurrent therapy with any drug active against HSV (acyclovir, valaciclovir, penciclovir, famciclovir, gancyclovir, foscarnet, cidofovir) or any immunosuppressive

2015 Clinical Trials

87. Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers

active against herpes viruses within 30 days prior to Day 1 including but not limited to: acyclovir, valacyclovir, famciclovir, penciclovir, ganciclovir and valganciclovir; 22.Use of any medication on a chronic basis; 23.Use of alcohol-containing, grapefruit-containing, or caffeine-containing foods or beverages within 72 hours prior to Check-in (Day -1); 24. Are taking or have utilized any drugs within 3 days prior to Day 1; alcohol or tobacco within 3 days prior to Day 1; or are a chronic alcohol

2015 Clinical Trials

88. Safety, Tolerability and Therapeutic Efficacy of Topical ZEP-3 Ointment (1.0%) for the Treatment of Cold Sores

-viral drug. Subject has had an infection with HSV-1 isolates know to be resistant to acyclovir, valacyclovir, famciclovir, or ganciclovir. Subject has had a herpes vaccine. Females during pregnancy, lactation or breastfeeding. Subject has a history of alcoholism or drug abuse within the preceding 12 months. Subject is currently enrolled in another clinical trial involving the use of a drug and/or a device. Any history which, in the Investigator's judgment, makes the subject ineligible or places

2015 Clinical Trials

89. Treatment of herpes zoster with ultrasound-guided superficial cervical plexus block Full Text available with Trip Pro

Treatment of herpes zoster with ultrasound-guided superficial cervical plexus block Herpes zoster most commonly occurs in elderly patients, and usually affects sensory neurons. Therefore, its characteristic symptoms are segmental pain, itching, and sensory changes in the affected areas. A 71-yr-old woman experienced painful herpetic rash on the right cervical 2-4 dermatomes for 16 days. Two days after the onset of the rash, she was diagnosed with herpes zoster, and prescribed 250 mg famciclovir

2015 Journal of Dental Anesthesia and Pain Medicine

90. Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

glucocorticoid use is prohibited for Phase Ia patients) Any known contraindication to Zostavax® vaccine, including allergy or sensitivity to gelatin or any other vaccine component Known HIV/AIDS Currently receiving radiation or chemotherapy for any type of malignancy Any current use (within the last 30 days) of acyclovir, valacyclovir, famciclovir, or foscarnet Receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non

2015 Clinical Trials

91. Immune Response to Shingles Vaccination

chickenpox or shingles in the past 5 years. VZV seronegative Taking systemic suppressive regular doses of drugs with anti-VZV activity such as acyclovir, famciclovir, or valacyclovir. Episodic use is allowed. For Cohort 1: medication cannot be taken 24 hours prior to or 30 days after receiving Zostavax per CDC recommendations. HIV seropositive. Hepatitis C infection or active Hepatitis B infection. History of a life-threatening allergic reaction (anaphylactic/anaphylactoid reaction) to gelatin, neomycin

2015 Clinical Trials

92. Postherpetic Wolf's isotopic response: Possible contribution of resident memory T cells to the pathogenesis of lichenoid reaction. (Abstract)

, Tokyo, 160-8582, Japan. Ohyama M M Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. eng Case Reports Letter 2015 10 16 England Br J Dermatol 0004041 0007-0963 0 Antigens, CD 0 Antigens, Differentiation, T-Lymphocyte 0 Antiviral Agents 0 CD69 antigen 0 Lectins, C-Type 452-06-2 2-Aminopurine QIC03ANI02 Famciclovir IM 2-Aminopurine administration & dosage analogs & derivatives Antigens, CD immunology Antigens, Differentiation, T (...) -Lymphocyte immunology Antiviral Agents administration & dosage Famciclovir Herpes Zoster drug therapy immunology pathology Humans Immunologic Memory immunology Lectins, C-Type immunology Lichenoid Eruptions etiology immunology pathology Male Middle Aged Recurrence T-Lymphocytes immunology 2015 6 27 6 0 2015 6 27 6 0 2016 10 19 6 0 ppublish 26114399 10.1111/bjd.13968

2015 British Journal of Dermatology

94. Management of STIs and related conditions in children and young people

– consider if all other treatment modalities failed Genital Herpes First episode Treat if within 5 days of start of episode or while new lesions are still developing. Child 1 month–2 years Aciclovir 100 mg orally five times a day for 5 days Child >2 years Aciclovir 200 mg orally five times a day for 5 days Recurrence If episodic or suppressive therapy is required see adult guideline. NB: Valaciclovir and famciclovir are not licensed for use in children. 45 Anogenital candidiasis Child 12 years Treatment

2010 British Association for Sexual Health and HIV

95. Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection

treatment (approved or investigational) at any time before screening Patient has a medical condition that requires frequent use of systemic acyclovir or famciclovir, systemic corticosteroids, potentially hepatotoxic drugs or nephrotoxic drugs or chemotherapy Patient has one or more additional known primary or secondary causes of liver disease, other than CHB; has a decompensated liver disease ; is a Liver transplant recipient or organ or bone marrow transplant recipient. History of any other acute

2014 Clinical Trials

96. Acyclovir Therapy for Genital Herpes Ulcers in HIV Negative African Women

by concordant rapid testing HSV-2 seropositive (Focus HerpeSelect EIA >3.4) At least one prior occurrence of GUD 18 to 50 years of age Exclusion Criteria: Current use, or use within the past 7 days, of acyclovir, valacyclovir, or famciclovir Prior hypersensitivity and/or allergic reaction to acyclovir Use of probenecid, which prolongs renal excretion of acyclovir Current use, or use within the past 28 days, of an investigational agent Currently pregnant or nursing Currently plan to become pregnant during

2014 Clinical Trials

97. Dopamine Rhythms in Health and Addiction

); antianginal agents; antiarrhythmics; antiasthma agents that are systemic corticosteroids; antibiotics; anticholinergics; anticoagulants; anticonvulsants; antidepressants; antidiarrheal preparations; antifungal agents (systemic); antihistamines (sedating); antihypertensives; anti-inflammatory drugs (systemic); antineoplastics; antiobesity; antipsychotics; antivirals (except for treatment of HSV with agents without CNS activity, e.g. acyclovir, ganciclovir, famciclovir, valacyclovir); anxiolytics

2014 Clinical Trials

98. Brain Inflammation and Function in Alcoholism

that are systemic corticosteroids; antibiotics; anticholinergics; anticoagulants; anticonvulsants; antidepressants; antidiarrheal preparations; antifungal agents (systemic); antihistamines (sedating); antihypertensives; anti-inflammatory drugs (systemic); antineoplastics; antiobesity; antipsychotics; antivirals (except for treatment of HSV with agents without CNS activity, e.g. acyclovir, ganciclovir, famciclovir, valacyclovir); anxiolytics; cough/cold preparations (dextromethorphan preparations

2014 Clinical Trials

99. MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)

allogeneic HSCT (previous autologous HSCT is acceptable) History of CMV end-organ disease within 6 months before randomization Has evidence of CMV viremia (if tested) at any time from either signing of the Informed Consent Form or the HSCT procedure, whichever is earlier, until the time of randomization. Received the following within 7 days before screening or plans to receive during the study: ganciclovir, valganciclovir, foscarnet, acyclovir, valacyclovir, or famciclovir Received the following within

2014 Clinical Trials

100. Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients

from samples collected within 14 days prior to enrollment. Local assays could be used to qualify the patient for enrollment. Received any of the following within 30 days prior to enrollment: ganciclovir, valganciclovir, foscarnet, cidofovir, acyclovir (>25 mg/kg/day IV), valacyclovir (>3 gm/day oral), famciclovir (>1500 mg/day oral), HCMV immune globulin, immune globulin (>500 mg/kg), or any other medication with anti-HCMV activity. Required mechanical ventilation within 7 days prior to enrollment

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>